NeuraStasis

Executive Summary

NeuraStasis is a San Diego-based medical device company pioneering non-invasive neurostimulation for acute stroke. Its lead product, StrokeGuard, is a wearable 'brain AED' that uses trigeminal nerve stimulation to enhance collateral blood flow, preserving brain tissue during the critical window before hospital treatment. Founded in 2015, the company addresses a major unmet need: there are currently no field-deployable devices to mitigate stroke damage during transport. StrokeGuard aims to reduce disability and extend the therapeutic window for thrombolysis or thrombectomy, potentially transforming emergency stroke care. The device has shown promise in early studies and is designed for use by first responders, offering a low-cost, scalable solution that could be widely adopted by emergency medical services. With validation from key opinion leaders and growing awareness of time-sensitive stroke interventions, NeuraStasis is positioned to disrupt the stroke care continuum, pending successful clinical and regulatory milestones.

Upcoming Catalysts (preview)

• Q3 2026Completion of Pivotal Trial Enrollment60% success
• Q4 2026FDA Breakthrough Device Designation70% success
• Q1 2027Strategic Partnership with EMS or Hospital Network50% success